Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04060212 · ClinicalTrials.gov registry record · NA

Mercury Metabolism by Bacteria in Humans

A NA study of Mercury--Toxicology, sponsored by University of Rochester.

Completed
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT04060212 is a NA study of Mercury--Toxicology that has completed, run by University of Rochester. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04060212, a NA study of Mercury--Toxicology, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate how the bacteria in your gut can improve the break-down and de-toxification of non-harmful levels of a naturally occurring form of mercury (methylmercury) that comes with eating fish. This research could help scientists and doctors understand whether or not mercury in fish that we are likely to eat poses any concern for the health of people.

Conditions Studied

Interventions

  • OTHER Tuna fish
  • DIETARY_SUPPLEMENT prebiotic

Study Locations (1)

New York

  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2019-10-01
Est. Completion 2023-08-31
Phase NA

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT04060212

The ClinicalTrials.gov registry entry for NCT04060212 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mercury--Toxicology appearing as the primary indexed condition, and to 2 interventions - of which Tuna fish is the first listed.

NCT04060212 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04060212 about?

NCT04060212 is a clinical study titled "Mercury Metabolism by Bacteria in Humans". The purpose of this study is to evaluate how the bacteria in your gut can improve the break-down and de-toxification of non-harmful levels of a naturally occurring form of mercury (methylmercury) that comes with eating fish. This research could help scientists and doctors understand whether or not m...

What is the current status of trial NCT04060212?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2019-10-01. Estimated completion is 2023-08-31.

What conditions does trial NCT04060212 study?

This clinical trial studies the following conditions: Mercury--Toxicology.

What interventions are being tested in trial NCT04060212?

The interventions under investigation include: Tuna fish (OTHER), prebiotic (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04060212?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04060212 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.